-+ 0.00%
-+ 0.00%
-+ 0.00%

Lantern Pharma Names CFO David Margrave Interim CEO

PUBT·11/18/2026 12:36:42
Listen to the news
Lantern Pharma Names CFO David Margrave Interim CEO
  • Lantern Pharma appointed Chief Financial Officer David Margrave interim CEO effective November 16, 2026.
  • Panna Sharma resigned as president, CEO and a board member effective November 15, 2026.
  • Margrave will serve until a permanent CEO is appointed. The board plans to promptly begin a successor search.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-052991), on November 18, 2026, and is solely responsible for the information contained therein.